Cundy Kenneth C

Xenoport, Inc.

SVP, Preclinical Development

Avg. Two Year Performance

307% Avg. Purchase Return 102% Compound

67% Avg. Sale Return 29% Compound

Holdings: 43.85K shares

Last Three Months: 24-Aug-24 -- 23-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Biotechnology

Drugs

Two Year Chart

24-Nov-22 -- 23-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions